CD8A and head and neck cancer: Interestingly, administrating nivolumab and ISA101 by boosting antigen-specific CD4+/CD8+ T cells and elevating the efficacy of anti-PD-1 therapy has promising outcomes in human papillomavirus-related head and neck cancers (56).